LON:AVCT - Avacta Group Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: GBX 0
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
GBX 239.50
▼ -19.5 (-7.53%)
1 month | 3 months | 12 months
Get New Avacta Group Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for AVCT and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for AVCT

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
GBX 0
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Avacta Group in the last 3 months. The average price target is GBX 0, with a high forecast of GBX 0 and a low forecast of £100,000. The average price target represents a -100.00% upside from the last price of GBX 239.50.

N/A

The current consensus among 0 investment analysts is to n/a stock in Avacta Group. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/22/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/21/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/19/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/17/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/16/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/16/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/15/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/14/2021

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
7/29/2020FinnCapReiterated RatingCorporate
i
6/8/2020FinnCapReiterated RatingCorporate
i
5/20/2020FinnCapReiterated RatingCorporate
i
5/11/2020FinnCapReiterated RatingCorporate
i
5/1/2020FinnCapReiterated RatingCorporate
i
4/22/2020FinnCapReiterated RatingCorporate
i
4/8/2020FinnCapReiterated RatingCorporate
i
4/2/2020FinnCapReiterated RatingCorporate
i
2/3/2020FinnCapReiterated RatingCorporate
i
1/23/2020FinnCapReiterated RatingCorporate
i
11/13/2019FinnCapReiterated RatingCorporate
i
10/21/2019FinnCapReiterated RatingCorporate
i
10/10/2019FinnCapReiterated RatingCorporate
i
6/20/2019FinnCapReiterated RatingCorporate
i
6/10/2019FinnCapReiterated RatingCorporate
i
6/3/2019FinnCapReiterated RatingCorporate
i
4/9/2019FinnCapReiterated RatingCorporate
i
2/4/2019FinnCapReiterated RatingCorporate
i
1/21/2019FinnCapReiterated RatingCorporate
i
12/10/2018FinnCapReiterated RatingCorporate
i
10/10/2018FinnCapReiterated RatingCorporate
i
10/2/2018FinnCapReiterated RatingCorporate
i
7/31/2018FinnCapReiterated RatingCorporate
i
7/24/2018FinnCapReiterated RatingCorporate
i
5/22/2018FinnCapReiterated RatingCorporate
i
4/16/2018FinnCapReiterated RatingCorporateGBX 200
i
1/22/2018FinnCapReiterated RatingCorporateGBX 200
i
1/15/2018FinnCapReiterated RatingCorporateGBX 200
i
11/21/2017FinnCapReiterated RatingCorporateGBX 200
i
11/15/2017FinnCapReiterated RatingCorporateGBX 200
i
10/10/2017FinnCapReiterated RatingCorporateGBX 200
i
10/4/2017FinnCapReiterated RatingCorporateGBX 200
i
8/24/2017FinnCapReiterated RatingCorporateGBX 200
i
8/7/2017FinnCapReiterated RatingCorporateGBX 200
i
5/30/2017FinnCapReiterated RatingCorporateGBX 200
i
5/22/2017FinnCapReiterated RatingCorporateGBX 200
i
4/24/2017FinnCapReiterated RatingCorporateGBX 200
i
4/4/2017Numis SecuritiesReiterated RatingBuyGBX 160
i
4/3/2017FinnCapReiterated RatingCorporateGBX 200
i
3/13/2017FinnCapReiterated RatingCorporateGBX 200
i
2/24/2017FinnCapReiterated RatingCorporateGBX 200
i
1/20/2017FinnCapReiterated RatingCorporateGBX 200
i
1/9/2017FinnCapReiterated RatingCorporateGBX 200
i
11/29/2016FinnCapReiterated RatingCorporateGBX 200
i
11/23/2016FinnCapReiterated RatingCorporateGBX 200
i
11/1/2016FinnCapReiterated RatingCorporateGBX 200
i
10/17/2016FinnCapReiterated RatingCorporate
i
9/22/2016FinnCapReiterated RatingCorporate
i
8/1/2016Numis SecuritiesReiterated RatingBuy
i
(Data available from 6/14/2016 forward)
Avacta Group logo
Avacta Group Plc offers reagents and therapeutics based on Affimer technology for diagnostic and research applications in the United Kingdom, North America, Asia, and rest of Europe. It operates in three segments: Diagnostics, Therapeutics, and Animal Health. The company develops custom Affimer proteins for customer products and in-house diagnostic assays. It also develops novel cancer immunotherapies combining proprietary platforms; and provides tools and contract services to assist diagnosis of conditions in animals to enable faster treatment for veterinarians. The company has a research partnership with Moderna Therapeutics; research collaboration with pre|CISION technology incorporates a substrate that is sensitive to cleavage by fibroblast activation protein; co-development partnership agreement with Bach Biosciences LLP to develop Affimer drug conjugate therapies; drug development collaboration with LG Chem Life Sciences; a partnership with Selexis to develop cell line for clinical manufacturing, and with Tufts University School of Medicine for developing Affimer drug conjugate therapies; a collaboration with Cytiva to develop and manufacture an Affimer-based point-of-care rapid test; and a collaboration with Adeptrix to develop Affimer-based COVID-19 antigen tests. Avacta Group Plc was incorporated in 2003 and is based in Wetherby, the United Kingdom.
Read More

Today's Range

Now: GBX 239.50
235
262

50 Day Range

MA: GBX 251.43
219
275

52 Week Range

Now: GBX 239.50
88.50
291.80

Volume

2,264,251 shs

Average Volume

2,781,623 shs

Market Capitalization

£606.95 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Avacta Group?

The following equities research analysts have issued research reports on Avacta Group in the last year: FinnCap.
View the latest analyst ratings for AVCT.

What is the current price target for Avacta Group?

0 Wall Street analysts have set twelve-month price targets for Avacta Group in the last year. has the lowest price target set, forecasting a price of £100,000 for Avacta Group in the next year.
View the latest price targets for AVCT.

What is the current consensus analyst rating for Avacta Group?

Avacta Group currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for AVCT.

What other companies compete with Avacta Group?

How do I contact Avacta Group's investor relations team?

Avacta Group's physical mailing address is Unit 20, Ash Way, WETHERBY, LS23 7FA, United Kingdom. The biotechnology company's listed phone number is +44-1904-217070. The official website for Avacta Group is www.avacta.com.